Introduction
============

22q11 deletion syndrome (22q11DS) has an incidence of approximately 1 in 4000 live births and classically comprises malformations of the cardiovascular system, thymus gland, parathyroid gland and craniofacial structures ([@bib50]). Haploinsufficiency of the transcription factor *TBX1* is considered to be the major underlying cause of the disorder. While the penetrance and expression of the deletion phenotype is very varied the cardinal features can be recapitulated by *TBX1* mutations in humans ([@bib39; @bib53; @bib62; @bib66]), mouse ([@bib21; @bib33; @bib36]), and zebrafish ([@bib42; @bib41]). In order to understand the role of *Tbx1* in development efforts have been made to identify *Tbx1* target genes using "candidate gene" or transcriptomics approaches.

Our previous work has examined the downstream transcriptional events of loss of *Tbx1* in dissected pharyngeal tissues ([@bib20; @bib43]). Several genes were identified and validated as differentially expressed in *Tbx1* mutants. In particular we were able to show a dysregulation of genes in the retinoic acid metabolism pathway that are likely to contribute to the phenotype ([@bib20; @bib45]). However, in these experiments the dissection includes cell types that do not express *Tbx1* and thus will either dilute some tissue specific expression changes, or add noise where tissue loss leads to a secondary expression change. We therefore aimed to repeat our analysis using only cells actively expressing from the *Tbx1* promoter. One of the *Tbx1* null alleles was created with a knock in of ß-galactosidase ([@bib33]). We investigated whether a fluorogenic substrate for ß-galactosidase could be used to isolate *Tbx1* expressing cells, firstly to further our target identification program, and secondly to demonstrate the general utility of this procedure in light of the thousands of such knock-ins available via the mouse gene trap program. FACS-Gal has been used previously on cultured cells ([@bib27]) but involves preparative procedures that could introduce noise into microarray analyses, and reduce cell viability especially when using early embryos. We therefore examined whether the FACS-Gal procedure could produce good quality microarray data from the material available from mid gestation embryos.

We utilized the *Tbx1*^+/*lacZ*^ × *Df1*/+ cross to obtain *Tbx1* null mutants to ensure equivalent fluorescence intensity from the *Tbx1*^*lacZ*^ allele in both genotypes. Df1 is a heterozygous deletion of 20 genes including *Tbx1* ([@bib33]), thus the hemizygously deleted *Df1* genes could be used as internal controls to assess the quality of the experiment. It is possible that genes in *cis* with *Tbx1* may have a haploinsufficient effect on gene expression, but *Tbx1*^+/*lacZ*^ and *Df1*/+ embryos have indistinguishable phenotypes and *Df1*/*Tbx1*^*lacZ*^ embryos have exactly the same phenotype as *Tbx1*^*lacZ*/*lacZ*^ mutants ([@bib33]) supporting their use as true *Tbx1* nulls. Since we were specifically interested in changes due to loss of *Tbx1* within cells normally expressing that gene, validation by in situ hybridisation was conducted using *Tbx1*^*lacZ*/*lacZ*^ mutants.

The quality of the microarray data was tested by analysing the down regulation of genes in *cis* with *Tbx1* and reduced to hemizygosity in the *Df1* deletion ([@bib32]), and by validating selected genes by RT-PCR in an independent sample. We selected the *Hes1* transcription factor, an effector of Notch signalling for further analysis. *Hes*^+/−^ and *Hes1*^−/−^ mouse embryos displayed a partially penetrant phenotype including pharyngeal arch artery (PAA) hypo/aplasia, outflow tract (OFT) misalignment, thymic agenesis and cleft palate --- defects seen in 22q11DS and *Tbx1* null embryos. Conditional mutagenesis indicated that lack of *Hes1* expression in the neural crest had no significant effect on great vessel development and a mild effect on thymic development. Concurrent ablation of *Hes1* expression in pharyngeal ectoderm and neural crest recapitulated much of the thymic phenotype of constitutive nulls, as well as yielding a small proportion of embryos with great vessel defects.

Results
=======

FACS-Gal enrichment of *Tbx1*-expressing cells
----------------------------------------------

In order to identify and enrich for *Tbx1* targets we performed a microarray comparing the gene expression profile of *Tbx1*-expressing cells from embryonic day 9.5 (E9.5) *Tbx1*^+/*lacZ*^ and *Df1*/*Tbx1*^*lacZ*^ (*Tbx1*-null) embryos. Whole embryos were dissociated at E9.5, a stage at which *Tbx1* expression is mainly restricted to the pharyngeal region, as recapitulated by the β-galactosidase reporter ([Figs. 1, 2](#fig1 fig2){ref-type="fig"}A--C). The *Tbx1*^*lacZ*^ allele was generated by inserting a lacZ construct into exon 5 of *Tbx1*, which encodes part of the DNA-binding domain ([@bib33]). Real-time PCR analysis has demonstrated that this allele represents a true null allele ([@bib64]). The *Tbx1*^*lacZ*^ allele was labelled using the fluorogenic substrate, 5-chloromethylfluorescein di-β-[d]{.smallcaps}-galactopyranoside (CMFDG) to compare nulls with heterozygous embryos. E9.5 embryos were collected and *Df1*/*Tbx1*^*lacZ*^ embryos were separated by phenotype from the *Tbx1*^+/*lacZ*^;*Df1*/+;wild type embryo pool for subsequent dissociation into a single cell suspension. After staining with the fluorescent substrate, CMFDG, cells were collected based on fluorescent intensity (above background) and cell viability ([Fig. 1](#fig1){ref-type="fig"}). FACS-Gal enrichment yielded an average number of 600 cells per E9.5 embryo. *Tbx1* driven lacZ expression was observed in pharyngeal endoderm, ectoderm and core mesoderm at this stage ([Figs. 2](#fig2){ref-type="fig"}A--C). Enrichment for *Tbx1* expressing cells was examined by RT-PCR using primers that detected only the wild type transcript, and primers that detected the IRES-lacZ. The IRES-lacZ could be detected in FACS-Gal fluorescent cell populations, but the wild type *Tbx1* transcript could only be detected in the heterozygote fluorescent population demonstrating we had captured the cells of interest ([Fig. 1](#fig1){ref-type="fig"}).

Microarray experiments were then carried out using Affymetrix mouse MOE430 v2.0 arrays consisting of over 34 000 well characterised mouse genes. Analysis of the microarray experiments was conducted using Genespring v4.2.1. Microarray experiments were carried out using RNA extracted from 3 pools of *Df1*/*Tbx1*^*lacZ*^ cells and 3 pools of *Tbx1*^+/lacZ^ cells. The three pools were sorted from independent groups of embryos to provide biological replication. Each pool of cells was obtained from a group of at least 8 E9.5 embryos (ranging in somite number from 17 s to 25 s). Pools of cells were used to minimise variation due to staging differences. (The average number of cells obtained per embryo was 535 cells per *Df1*/*Tbx1*^*lacZ*^ embryo and 646 cells per *Tbx1*^+/*lacZ*^ embryo.) Due to the limited number of cells obtained, PCR amplification was used to generate sufficient RNA for microarray analysis.

To assess the sensitivity of the approach for microarray we examined the expression levels of genes reduced to hemizygosity in this cross. It has been shown previously that the *Df1* genes are decreased to approximately 50% of wild type expression levels in *Df1*/+ heterozygotes and they do not exhibit dosage compensation ([@bib43]). Seventeen of 20 *Df1* genes represented on the array were expressed above threshold levels, and 16 of these 17 were down regulated to an average of 0.611 ± 0.096 (mean ± SD) in *Df1*/*Tbx1*^*lacZ*^ arrays compared to *Tbx1*^+/*lacZ*^ arrays ([Table 1](#tbl1){ref-type="table"}) indicating the sensitivity of the experiment in detecting downregulated genes. The one of 17 genes upregulated was *Es2el*, whose upregulation is a previously described artifact secondary to the fact that this gene is at the *Df1* deletion breakpoint ([@bib20; @bib43]).

In order to identify non-*Df1* deletion genes which were downregulated in *Df1*/*Tbx1l*^*acZ*^ cells, we chose a statistical filter which selected the majority (14/16) of down regulated *Df1* genes as having significantly reduced expression. This filter was downregulated to at least 0.83 in 5 out of 6 *Df1*/*Tbx1l*^*acZ*^ arrays compared to *Tbx1*^+/*lacZ*^ arrays, with *p* \< 0.05 using the Benjamini and Hochberg false discovery rate correction. This resulted in a total of 1553 unique sequences which were downregulated at least to the same degree as most *Df1* genes ([Supplementary Table 1](#app1){ref-type="sec"}). The full dataset is available at ArrayExpress, accession E-MEXP-2096.

Validation of downregulated genes by qRT-PCR
--------------------------------------------

Validation focused on downregulated genes because *Tbx1* has been demonstrated to be a transcriptional activator ([@bib1; @bib53; @bib59]). Quantitative, real-time PCR (qRT-PCR) was carried out to confirm gene expression changes using RNA amplified from an independent pool of *Df1*/*Tbx1*^*lacZ*^ and *Tbx1*^+/*lacZ*^ cells collected by FACS from at least 10 E9.5 *Df1*/*Tbx1*^*lacZ*^ embryos and *Tbx1*^+/*lacZ*^ embryos.

Genes were selected for independent validation by qRT-PCR based on their expression pattern, known or potential function in pharyngeal or heart development, and significant downregulation in the microarray experiments. Genes were also chosen based on their previous identification in other *Tbx1* microarrays. Altogether, 30 genes downregulated in the absence of *Tbx1* were analysed by qRT-PCR; 18 (60%) showed significant (*p* \< 0.05) downregulation in *Df1*/*Tbx1*^*lacZ*^ cells and 12 genes showed no appreciable changes in expression ([Table 2](#tbl2){ref-type="table"}).

The most strikingly altered gene was *Nkx2.6*, whose expression was completely abolished in *Tbx1*-null cells by qRT-PCR ([Table 2](#tbl2){ref-type="table"}). Other genes which were downregulated greater than 3-fold were *Notch3* and *Hes1*, members of the Notch signalling pathway, *Smad7*, required for heart development ([@bib3]), and *Cxcl4* and *Cdh1* whose role in pharyngeal or heart development have yet to be characterised. Downregulation of a number of genes with a known function in the pharyngeal apparatus or the heart (*Sema3c*, *Isl1*, *Tbx18*, *Bmpr1a*, *Dsg2* and *Gsk3β*) were also validated by qRT-PCR with *Sema3c* exhibiting the greatest downregulation, to 0.360 ± 0.170, in *Tbx1*-null cells. The remaining validated genes (*Crb3*, *Plek*, *Slit2*, *Lztfl1*, *Tle4* and *Daam1*) represent additional, novel factors which have not previously been shown to be involved in development of the pharyngeal system and its derivatives.

To demonstrate the utility of the FACS-Gal approach in identifying genes potentially contributing to *Tbx1* loss of function phenotypes, we chose *Hes1* for further functional analysis. Targeted mutants were already available, and other Notch pathway genes have previously been implicated in cardiovascular morphogenesis as discussed below.

*Hes1* is downregulated in the pharyngeal apparatus of *Tbx1* null embryos
--------------------------------------------------------------------------

In situ hybridization revealed that *Hes1* is expressed in the pharyngeal region at E9.5 ([Figs. 2](#fig2){ref-type="fig"}D, E, G) and that this expression is diminished, particularly in mesoderm and endoderm of *Tbx1*^−/−^ embryos of the same stage ([Figs. 2](#fig2){ref-type="fig"}F, H), consistent with diminished *Hes1* levels in FACS sorted *Tbx1*^−/−^ cells. Expression of *Tbx1* in pharyngeal ectoderm at E8.5 is especially important for the great vessel defects typically seen in 22q11DS ([@bib44; @bib65]). At the protein level, Hes1 is broadly expressed in pharyngeal endoderm, ectoderm and pharyngeal mesenchyme ([Fig. 2](#fig2){ref-type="fig"}I) at this stage. Dual staining reveals co-expression of Hes1 and Tbx1 in pharyngeal ectoderm, endoderm and mesoderm ([Fig. 2](#fig2){ref-type="fig"}I). Together, these data suggest a possible role for *Hes1* in the morphogenesis of the pharyngeal apparatus.

*Hes1* mutant embryos have abnormalities of the pharyngeal arch arteries
------------------------------------------------------------------------

A major feature of *Tbx1* heterozygous animals and 22q11DS patients is defective great vessel development secondary to abnormal growth and remodelling of the 4th PAA ([@bib33]). We therefore assessed the growth and patency of *Hes1* mutant PAAs at E10.5 using ink injection and found a defect in 13/40 (32.5%) *Hes1*^−/−^ embryos analysed on an MF1 background ([Table 3](#tbl3){ref-type="table"}), including hypo/aplasia of the 3rd, 4th ([Fig. 3](#fig3){ref-type="fig"}D) and 6th arch arteries ([Fig. 3](#fig3){ref-type="fig"}F), persistent 1st and 2nd arch arteries ([Fig. 3](#fig3){ref-type="fig"}E and not shown), and aberrant branching of the arch arteries (arrows and inset, [Fig. 3](#fig3){ref-type="fig"}E). We also detected the same range of PAA defects in a smaller proportion of heterozygous embryos (13/80, 16%) ([Table 3](#tbl3){ref-type="table"}, [Figs. 3](#fig3){ref-type="fig"}B, C), although defects involved hypoplasia rather than aplasia.

*Hes1* mutants exhibit defects in vascular smooth muscle patterning
-------------------------------------------------------------------

Defective PAA development can occur due to a failure of endothelial tube formation or aberrant growth and remodelling. We first analysed formation of endothelial tubes using Endomucin, an endothelial cell marker. *Hes1* mutant embryos with hypoplastic PAAs or PAAs non-patent to ink still retained expression of Endomucin surrounding the arteries even though they were very small at E10.5 ([Fig. 4](#fig4){ref-type="fig"}B). Thus, initial formation of the capillary tubes appears to occur normally, although growth of the arteries is affected. The non-endothelial component of the developing PAAs derives from the surrounding neural crest (NC) which differentiates into smooth muscle α-actin (α-SMA)-positive vascular smooth muscle (VSM) surrounding the PAAs ([@bib22; @bib29]). Wild type embryos at E11.5 showed strong expression of α-SMA surrounding the 3 rd, 4th and 6th PAAs ([Fig. 3](#fig3){ref-type="fig"}C). However, in *Hes1*^−/−^ mutants which exhibit hypoplastic PAAs, α-SMA staining is absent (PAA3, red arrow in [Fig. 4](#fig4){ref-type="fig"}D) or diminished (PAA4, white arrow in [Fig. 4](#fig4){ref-type="fig"}D). These results demonstrate that during PAA morphogenesis *Hes1* is required for normal VSM development.

*Hes1*^−/−^ mutants exhibit great vessel and intracardiac defects
-----------------------------------------------------------------

Defective growth and remodelling of the PAAs produces later defects of the great vessels. We examined E14.5 to E15.5 embryos on a pure MF1, and a mixed MF1;C57Bl/6 (MF1;Bl6) background, by MRI, histology and ink injection. A proportion of *Hes1*^−/−^ embryos exhibited cardiovascular defects (7/40, 17.5%, both genetic backgrounds; 4/23 (17%) MF1;Bl6 and 3/17 (17%) MF1) ([Table 4](#tbl4){ref-type="table"}, [Fig. 5](#fig5){ref-type="fig"}). We observed defects in OFT alignment in 3/40 (8%) *Hes1*^−/−^ homozygotes (1/23 (4%) MF1;Bl6 and 2/17 (12%) MF1) ([Table 4](#tbl4){ref-type="table"}, [Figs. 5](#fig5){ref-type="fig"}K, L) which were accompanied by a ventricular septal defect (VSD) ([Fig. 5](#fig5){ref-type="fig"}H). Great vessel defects (4/23 (17%) MF1;Bl6 and 1/17 (6%) MF1) included right-sided aortic arch (RAA) ([Figs. 5](#fig5){ref-type="fig"}B, C), interruption of the aortic arch type B (IAA-B) ([Fig. 5](#fig5){ref-type="fig"}C) and isolation of the right subclavian artery (I-RSA) ([Figs. 5](#fig5){ref-type="fig"}D, F) which branched off the pulmonary trunk instead of the right common carotid. These defects represent aberrant development of the 4th PAA. Some embryos exhibited right-sided ductus arteriosus, a 6th arch artery defect ([Fig. 5](#fig5){ref-type="fig"}B). The phenotype of these *Hes1*^−/−^ mutants is consistent with the earlier PAA defects present at E10.5.

Genetic background appeared to affect the penetrance of the *Hes1* mutant phenotype. On an MF1 background, a proportion of *Hes1*^−/−^ mice exhibit neural tube defects and are also embryonic lethal prior to E15.5 resulting in lower than expected numbers of *Hes1*^−/−^ mutants according to the predicted Mendelian ratios. However, on a mixed background, no neurulation defects were identified and all genotypes were present at the expected ratios ([Supplementary Table 2](#app1){ref-type="sec"}). This suggests that the proportion of MF1 *Hes1*^−/−^ homozygotes with a heart defect could be higher if investigated earlier. At E11.5, we noted that a number of *Hes1*^−/−^ embryos on an MF1 background exhibit body hemorrhage and the yolk sac of these embryos appear to lack large vitelline vessels ([Supplementary Fig. 1](#app1){ref-type="sec"}), suggesting the earlier lethality is due to a more serious defect in cardiovascular development. Thus, the mixed MF1;Bl6 background appears to allow *Hes1*^−/−^ embryos to survive at least until E15.5.

In contrast to the PAA defects detected in *Hes1*^+/−^ embryos at E10.5, no great vessel abnormalities were found in *Hes1*^+/−^ heterozygotes at E15.5 ([Table 4](#tbl4){ref-type="table"}) indicating that these defects may largely recover later in development. *Tbx1* heterozygotes display a similar background dependent rescue of PAA malformations as embryogenesis proceeds ([@bib54]). However, one MF1;Bl6 *Hes1*^+/−^ embryo was slightly growth delayed in comparison to its littermates and had a cleft palate, and another MF1 *Hes1*^+/−^ embryo had dextroposition of the heart ([Table 4](#tbl4){ref-type="table"}) indicating potential haploinsufficiency.

Fgf8 is required for PAA morphogenesis ([@bib9]). Furthermore, dominant negative interference of the Notch pathway in the second heart field gives rise to a defect in epithelial to mesenchymal transition that, in ex vivo culture, can be rescued by Fgf8 ([@bib16]). Thus, down regulation of Fgf8 may contribute to both the arch artery and outflow tract abnormalities observed in *Hes1* nulls. However, no alteration of *Fgf8*, or *Etv4*, a readout for Fgf activity ([@bib35]) was detected at E8.5, while *Fgf8*, *Fgf10* and *Etv4* appeared unaffected at E9.5 as well ([Supplementary Fig. 2](#app1){ref-type="sec"}). qRT-PCR detected no quantitative change in *Etv4* or *Etv5* expression at both stages ([Supplementary Fig. 2](#app1){ref-type="sec"}).

MRI of *Hes1* mutant embryos reveals additional 22q11DS-like malformations
--------------------------------------------------------------------------

One of the original descriptions of *Hes1* null mutants commented upon lack of thymus gland development ([@bib57]). To quantify this and survey the anatomy of mutants we used MRI of E15.5 embryos on both a mixed MF1;C57Bl6 and pure MF1 background. We found highly penetrant thymic hypo/aplasia on both backgrounds ([Table 4](#tbl4){ref-type="table"}, [Fig. 5](#fig5){ref-type="fig"}P). Of particular note is the presence of cleft palate in 9/15 (60%) MF1 *Hes1*^−/−^ embryos and 9/23, (39%) MF1;C57Bl6 *Hes1*^−/−^ mutants ([Table 4](#tbl4){ref-type="table"}, [Fig. 5](#fig5){ref-type="fig"}N), which is observed in *Tbx1*^−/−^ embryos of the same stage ([@bib21]).

Expression of other notch pathway genes is altered in FACS isolated *Tbx1*-null cells
-------------------------------------------------------------------------------------

*Hes1* is the main effector of Notch signalling and Notch pathway genes have previously been implicated in cardiovascular development ([@bib14]). We therefore analysed expression of Notch pathway genes by qRT-PCR to investigate whether *Hes1* may be downregulated in *Tbx1* mutants due to aberrant Notch signalling. In *Df1*/*Tbx1*^*lacZ*^ cells, the Notch receptors, *Notch3* and *Notch4* are downregulated while *Notch1* and *Notch2* are upregulated. In addition, the Notch ligand, *Dll1* and DNA-binding transactivator, *Rbpj* are also upregulated ([Supplementary Fig. 3](#app1){ref-type="sec"}). These results could suggest that *Hes1* may act downstream of *Notch3* or *Notch4*. Upregulation of other Notch pathway members could be due to functional compensation or negative feedback from loss of *Hes1*. The incomplete penetrance of pharyngeal-derived defects in *Hes1* mutants suggest a possible functional redundancy with other Hes-related genes, especially since *HeyL;Hey1* double mutants, but not single mutants, have heart defects ([@bib8]). In addition, Hes1, Hey1 and Hey2 bind to promoters of an overlapping set of genes (M. Gessler, personal communication). In *Tbx1*-null cells, *Hey1* expression is diminished but *Hey2* is unchanged and *HeyL* is upregulated 3.4 fold ([Supplementary Fig. 3](#app1){ref-type="sec"}).

*Hes1* is required in embryonic pharyngeal ectoderm for normal thymic development
---------------------------------------------------------------------------------

Conditional dominant negative interference of Notch signalling in cardiac neural crest cell progenitors (using *Pax3Cre* and *Wnt1Cre*) results in pulmonary stenosis and aortic arch patterning defects ([@bib15]). Thus, even though *Tbx1* is not expressed in neural crest, we investigated *Hes1* requirements in these cells as the effect of loss of *Tbx1* on *Hes1* expression might be indirect. We therefore crossed *Hes1*^+/−^;*Wnt1Cre* mice to *Hes1*^fl/fl^ mice using a conditional allele for *Hes1* ([@bib24]), and assessed defects in pharyngeal structures. Although it can only act as a surrogate for recombination at the *Hes1* locus, the ROSAR26R reporter confirmed strong Cre activity in neural crest lineages within this cross (i.e. on the same genetic background ([Figs. 6](#fig6){ref-type="fig"}A--C)). Thymic hypo/aplasia was observed in 3 of 21 *Hes1*^*fl*/−^ embryos, 2 of 31 embryos hemizygous for *Hes1* in neural crest only, and in 10 of 26 (38%) *Hes1*^*fl*/−^;*Wnt1Cre* embryos. Thus, complete loss of *Hes1* in neural crest increased the frequency of thymic hypoplasia; however, there were no instances of thymic aplasia in these crosses. Great vessel defects were not apparent in any embryos ([Table 5](#tbl5){ref-type="table"}). In summary, there is not a major requirement for *Hes1* in the neural crest lineage although a contributory role in thymus development was detected.

*Tbx1* is required in pharyngeal epithelia for normal great vessel morphogenesis ([@bib65]). We have recently refined this to a requirement in pharyngeal ectoderm ([@bib44]). Thus, to investigate the requirement for *Hes1* in ectoderm we used the *Ap2αCre* driver which effects recombination in both ectoderm and neural crest, the results being compared to the *Wnt1Cre*, neural crest only, conditionals. The ROSAR26R reporter was used to assess recombination within this cross and confirmed strong Cre activity in the embryonic surface ectoderm and neural crest lineages ([Figs. 6](#fig6){ref-type="fig"}D--F). 26 of 32 (81%) *Hes1*^*fl*/−^;*Ap2αCre* as compared to 2 of 23 *Hes1*^*fl*/−^ (9%) embryos exhibited thymic hypo/aplasia ([Table 5](#tbl5){ref-type="table"}, [Figs. 6](#fig6){ref-type="fig"}K--M). This recapitulates much of the thymic malformation seen in the constitutive nulls, (thymic aplasia was noted in seven cases). In two of 36 (6%) *Hes1*^*fl*/−^;*Ap2αCre* embryos we observed a great vessel defect. One embryo had a branched right common carotid and the other had isolation of the right subclavian artery, abnormalities which occur due to defective development of the 3rd and 4th PAA, respectively ([Figs. 6](#fig6){ref-type="fig"}H, I). This frequency of defects does not fully reproduce that seen in constitutive mutants suggesting a modifying effect of genetic background or that great vessel morphogenesis requires *Hes1* expression in additional tissues. In summary, ectodermal expression of *Hes1* makes a major contribution to thymus development and also plays a role in PAA development. As *Ap2αCre* effects recombination in both ectoderm and neural crest, a synergistic effect of crest ablation of *Hes1* in the absence of ectodermal expression cannot be ruled out.

*Hes1* is required for normal cell proliferation in the pharyngeal ectoderm
---------------------------------------------------------------------------

Previous analyses have demonstrated impairment of cell cycle progression in the pharyngeal endoderm and second heart field, but not the myocardium, of *Hes1* mutants ([@bib46]). We therefore asked whether pharyngeal ectoderm was similarly affected. PAA and thymic development requires *Tbx1* at stage E8.5 ([@bib60]). At this stage, we observed decreased proliferation in the ectoderm --- a reduction in the number of phospho-histone H3 positive cells (from 20 to 14%) in *Hes1* nulls compared to wild type controls ([Fig. 7](#fig7){ref-type="fig"}; *p* \< 0.02). There was also an increase in the number of Ki67 negative (quiescent) cells (from 6 to 9.6%), ([Fig. 7](#fig7){ref-type="fig"}; *p* \< 0.05). There was no alteration in apoptosis in the pharyngeal ectoderm or neural crest at E9.5 (assayed using a caspase3 antibody (not shown)). The sections studied are from the same embryos used by [@bib46]. Our results indicate that *Hes1* is important for proliferation of the pharyngeal ectoderm, which may in turn affect morphogenesis of the thymus and PAAs. Altered proliferation is unlikely to be secondary to decreased Fgf8 signalling at this stage, since expression of *Fgf8* itself and downstream readout of Fgf activity are not detectably altered ([Supplementary Fig. 2](#app1){ref-type="sec"}).

Discussion
==========

Our studies demonstrate that FACS-Gal is a useful technique to enhance the power of transcriptomics studies of murine embryogenesis. FACS-Gal can make use of the large existing repository of β-galactosidase-trapped ES lines now encompassing approximately 33% of all mouse genes (<http://www.genetrap.org/index.html>). Isolation of the expressing cells of interest will enrich for autonomous effects and reduce noise from non-expressing tissues. Moreover, the existence of Cre-reversible traps opens the way to within group comparisons of flow-sorted cells, one pool having had expression restored using a tamoxifen activated Cre enzyme.

We used FACS-Gal to analyse gene expression changes between *Tbx1*-null and *Tbx1*-heterozygous cells and identified a list of potential *Tbx1* targets including *Hes1*. Recently, an independent microarray screen also identified *Hes1* as downregulated in dissected *Tbx1*^−/−^ caudal pharyngeal tissue ([@bib30]). These experiments were aimed at identifying dysregulated genes in the secondary heart field, and were not restricted to *Tbx1*-expressing cells. Nevertheless there were genes identified in common with those reported here. In particular, *Hes1* was downregulated 2.5 fold at E8.75. Four other genes were downregulated by microarray and confirmed by qRT-PCR in both studies: *Nkx2.6*, *Crb3*, *Isl1*, and *Dab2*. Thus these five genes represent excellent candidates to contribute to the phenotype caused by loss of *Tbx1*. *Nkx2.6* was almost undetectable by qRT-PCR in the *Tbx1*^−/−^ cells, and missense mutation of the gene has been described in common arterial trunk malformation in humans ([@bib13]). *Nkx2.6* is expressed transiently in the mouse embryonic pharyngeal endoderm, but *Nkx2.6*^−/−^ mice are apparently normal ([@bib55]). However, *Nkx2.5* expression expands into *Nkx2.6* expression domains in these mutants suggesting a regulatory compensation by Nkx2.5. Consistent with this hypothesis, *Nkx2.6*^−/−^*;Nkx2.5*^−/−^ embryos had an abnormal, dilated pharynx with reduction in the numbers of endodermal cells, phenotypes not observed in *Nkx2.5*^−/−^ single mutants ([@bib56]). However, the *Nkx2.6*^−/−^ mouse line is no longer available to pursue the possibility of *Tbx1*:*Nkx2.6* interaction.

We focused on *Hes1* as a gene worth investigating for a possible biological role in the morphogenesis of structures requiring *Tbx1*. *Hes1* represents one of the main effectors of Notch signalling and has been shown to play diverse roles in development ([@bib23]). *Hes1* is known to be involved in thymic morphogenesis ([@bib57]) and recently, *Hes1* has been shown to play a role in the development of the outflow tract ([@bib46]). However, to date there has been no published role for *Hes1* in pharyngeal arch artery or palate development. Numerous members of the Notch pathway play important roles in cardiovascular development, including the Notch ligand, *Jag1* and the Notch target genes, *Hey1*, *Hey2* and *HeyL* ([@bib6; @bib7; @bib8; @bib10; @bib26; @bib25; @bib28; @bib37; @bib49]). These Notch pathway genes are known to be important for processes such as arterial-venous differentiation and targeted Notch pathway mutants exhibit heart defects including VSDs, atrioventricular valve defects, tetralogy of Fallot and cardiomyopathy ([@bib6; @bib7; @bib8; @bib10; @bib26; @bib25; @bib49]). Dominant negative repression of Notch signalling within the neural crest (NC-DNMAML mutants) causes a range of heart defects, predominantly pulmonary stenosis and great vessel defects ([@bib15]). SHF-specific inhibition of Notch signalling (SHF-DNMAML mutants) also results in great vessel defects as well as OFT alignment and septation defects ([@bib16]). However, *Hes1* is the first Notch effector mutant described as having PAA abnormalities. While it is possible that functional redundancy among related Notch pathway members may explain this inconsistency, our findings reveal that *Hes1*^−/−^ mutants exhibit a spectrum of PAA-derived malformations similar to those which occur in DNMAML mutants ([@bib15]) suggesting that *Hes1* may play a dose-dependent role in mediating the effects downstream of Notch signalling in PAA development and remodelling. *Hes*-related genes are expressed in overlapping domains with *Hes1* within pharyngeal tissues including the neural crest and pharyngeal endoderm ([@bib15]). This potential for redundancy may provide an additional explanation for the partially penetrant *Hes1* null phenotype we observed. Indeed, we observed a 3.4 fold increase in the level of HeyL expression in *Tbx1*^−/−^ cells. *Hey* gene functional redundancy could affect analysis of a genetic interaction between *Tbx1* and *Hes1* in doubly heterozygous mice. It will therefore be interesting in the future to determine whether DNMAML and *Tbx1* mutants show an epistatic relationship during development.

The spectrum of PAA malformations in *Hes1* mutants ranges from persistence of the 1st and 2nd arch arteries to hypo/aplasia and aberrant branching of the caudal PAAs. This phenotype is similar to NC ablation phenotypes ([@bib17]). Thymic and palatal defects are also found in several neural crest gene mutants ([@bib11; @bib47]). *Hes1*^+/−^ heterozygotes exhibit PAA defects at E10.5 however, they exhibit hypoplasia and aberrant PAA branching rather than aplasia. The relatively mild phenotype may represent an intermediate defect in PAA patterning from which embryos recover during development. This may help to explain why the percentage of embryos with PAA defects has decreased at E15.5 in *Hes1*^−/−^ nulls and why no *Hes1*^+/−^ heterozygotes appeared with PAA-derived defects later in development. A similar reduction in PAA derivative defects is seen in *Tbx1* mice ([@bib31]).

Here, we show that *Hes1* and *Tbx1*^+/−^ mutants exhibit an overlapping phenotype, specifically 4th PAA hypo/aplasia, thymic hypo/aplasia and cleft palate. In PAA development, *Tbx1* is known to play a non-cell autonomous role in controlling VSM differentiation ([@bib2; @bib31; @bib65]). Similarly, *Hes1* mutants exhibit a defect in VSM patterning of the PAAs which may be due to decreased NC contribution ([@bib46]) and/or a failure of the NC to properly differentiate, suggesting that *Hes1* may act downstream of *Tbx1* to effect its role in PAA morphogenesis. It is possible that *Hes1* acts as an indirect target of *Tbx1* through downregulation of the Notch signalling pathway. In support of this role, downregulation of Notch signalling within the NC causes a failure of VSM differentiation and SHF-DNMAML mutants exhibit aberrant CNC migration both leading to PAA defects ([@bib16; @bib15]).

*Tbx1* is required within the pharyngeal ectoderm for PAA, thymus and palate development ([@bib44]). *Tbx1* is not expressed in the NC but we wanted to ascertain what role *Hes1* played in this tissue. We specifically ablated *Hes1* within the NC using *Wnt1Cre*. No great vessel defects were observed in these embryos, the only abnormalities involving thymus gland hypoplasia. We therefore used the *Ap2αCre* driver and a conditional *Hes1* allele to test *Hes1* requirements within the pharyngeal ectoderm. We observed a low frequency great vessel defect, however thymic hypo/aplasia was prevalent in *Ap2αCre* conditional *Hes1* mutants, suggesting a non-cell autonomous role of *Hes1* to organogenesis similar to *Tbx1* ([@bib44]). It remains to be determined what role, if any, Notch signalling plays within the pharyngeal ectoderm. However, we surmise that expression of *Hes1* in tissues other than ectoderm and neural crest will contribute to cardiovascular morphogenesis because the pharyngeal ectoderm-specific knockout of *Hes1* did not recapitulate the spectrum and frequency of defects seen in constitutive *Hes1* nulls. In particular, second heart field and pharyngeal endoderm lineages may be important in this regard. Disruption of Notch signalling within the SHF causes OFT alignment and septation defects and great vessel abnormalities (among other cardiovascular malformations). These defects occur due to aberrant signalling between the SHF and the NC leading to a decrease in CNC migration through the pharyngeal arches ([@bib16]). *Hes1* mutants exhibit reduced proliferation within the SHF and show similar CNC migration defects ([@bib46]). It will be interesting to determine whether SHF-specific Notch deletion mutants also exhibit decreased proliferation of SHF progenitors and to examine the SHF-specific role of *Hes1* in OFT morphogenesis. The SHF-DNMAML mutants also had defective endothelial to mesenchymal transition in endocardial cushion explant tissue ([@bib16]). Addition of exogenous Fgf8 to these cultures was sufficient to rescue the defect. As *Fgf8* is also intimately involved in PAA morphogenesis we examined *Fgf8* and *Fgf10* expression, together with Fgf activity as determined by *Etv4*/*Etv5* expression, in *Hes1* null embryos, but no abnormalities were observed.

Together, these data support a non-cell autonomous role for *Hes1* in thymic and, to a lesser extent, PAA morphogenesis and adds to recent data indicating the importance of the embryonic pharyngeal ectoderm in this process. One possibility is that *Hes1* regulates an aspect of signalling from the pharyngeal ectoderm to the neural crest or other mesenchymal cell types, as we have postulated for *Gbx2* ([@bib2]). A second possibility is that the moderate decrease in cell proliferation seen in pharyngeal ectoderm of *Hes1*^−/−^ embryos could result in a decrease in the number of the relevant signalling cell lineages. Despite the comparatively restricted neural crest conditional phenotype, a role for *Hes1* in regulating differentiation of the postmigratory NC cannot be excluded since the *Ap2αCre* driver effects recombination in neural crest as well as ectoderm. *Hes1* has previously been shown to play dual roles within the same tissue in maintaining proliferation of stem cells and promoting differentiation depending on the developmental stage ([@bib38]). We detected reduced proliferation in pharyngeal ectoderm of *Hes1* null embryos, but markers for progenitor differentiation are not available for this tissue.

*Hes1* has primarily been described as an effector of Notch signalling, but there is evidence that *Hes1* also acts independently of Notch through signalling pathways including Shh and Vegf ([@bib5; @bib12; @bib18]). Furthermore, *Tbx* transcription factors have been shown to regulate members of the *Hes*-related family in heart development ([@bib48]). These results suggest that a conserved regulatory pathway may exist between T-box transcription factors and members of the *Hes* family. *Tbx1* regulation of the Notch pathway has been observed in the developing ear. However, in this situation, loss of *Tbx1* results in some members of the *Tbx1*-dependent cell population switching to a neurogenic fate, an event associated with activation of the Delta-Notch pathway. It is not known whether this is a direct or indirect regulation ([@bib61]).

The decreased expression of *Hes1* in the *Tbx1LacZ* expressing, *Tbx1* null cells could be explained by several mechanisms (see [Supplementary Fig. 4](#app1){ref-type="sec"}), including direct transcriptional regulation. Transfection assays to date have so far failed to support direct action of Tbx1 on the *Hes1* promoter (data not shown), thus the molecular basis of the *Hes1* regulation by *Tbx1* remains to be elucidated. Since *Tbx1* regulates cell proliferation, loss of *Tbx1* could reduce the number of *Hes1* expressing cells, detected as reduced *Hes1* transcript abundance by FACS-GAL. As *Hes1* is also involved in controlling cell proliferation, this would result in overlap between the *Hes1* and *Tbx1* loss of function phenotypes in the absence of a direct regulatory relationship. A third possibility is that *Tbx1* directly or indirectly controls expression of other Notch pathway genes (e.g. *Notch3*, which had reduced expression in the FACS-Gal enriched *Tbx1*-null cells). In this model, *Hes1* would be indirectly downregulated as a consequence.

This work demonstrated the utility of FACS-Gal for identifying genes dysregulated in embryonic models of human disease. *Hes1* was validated as downregulated in *Tbx1* null embryos and shown to be required for the normal formation of pharyngeal-derived structures. In particular, expression of *Hes1* in embryonic pharyngeal ectoderm was shown to be required for normal thymus development and makes a contribution to pharyngeal arch artery morphogenesis. Thus, *Hes1* downregulation may contribute to the *Tbx1* loss of function phenotype.

Materials and methods
=====================

Mice
----

*Tbx1*^+/*lacZ*^ and *Df1*/+ mice have been described previously and were maintained on a C57BL/6 background ([@bib32; @bib33]). *Hes1*^+/−^ mice ([@bib19]) were kindly provided by Francois Guillemot, National Institute of Medical Research, UK and maintained on a MF1 and CD1 background. *Wnt1Cre* mice ([@bib4]) were kindly provided by Andrew Copp, Institute of Child Health, University College London, London, UK and maintained on a C57BL/6 background. *Ap2αCre* mice ([@bib34]) were obtained from Anne Moon, University of Utah School of Medicine, Salt Lake City, Utah, USA and maintained on a C57BL/6 background. Genotyping of embryos was carried out on yolk sac or tail tip genomic DNA as previously described ([@bib19; @bib32; @bib33]). The *Hes1* conditional allele was obtained from R. Kageyama ([@bib24]), and the ROSAR26R reporter originated in the Soriano lab ([@bib52]). Mouse work was carried out in accordance with British Home Office regulations.

CMFDG labelling of a single cell suspension
-------------------------------------------

E9.5 embryos were dissected out in DMEM + 25 mM HEPES containing 10% FCS. The embryos were staged by somite counting and *Df1*/*Tbx1*^*lacZ*^ embryos were separated from *Df1*/+, *Tbx1*^+/*lacZ*^ and wild type embryos. CMFDG loading was carried out using the Detectagene green CMFDG lacZ gene expression kit (Molecular Probes). Following three rinses in PBS, embryos were incubated in 0.25% trypsin (Gibco) in PBS for approximately 30 min during which the embryos were dissociated into a single cell suspension by trituration. The single cell suspension was spun down at 300 x g for 3 min and resuspended in pre-warmed (10 min at 37 °C) 50 μM CMDFG, 200 μM verapamil in 5% FCS/DMEM + 25 mM HEPES and incubated for 30 min at 37 °C, 5% CO~2~. Following incubation, the cells were placed on ice and diluted to approximately 1--3 million cells/mL with 5%FCS/DMEM + 25 mM hepes. 1 mM PETG was added to stop the reaction and 1.5 μM propidium iodide (PI) was added to identify dead cells. Cells were flow-sorted as soon as possible.

FACS analysis
-------------

Single cell suspensions were sorted using the Beckman Coulter Epics Altra cell sorter (High Wycombe) and analysed using the Expo2 software (Beckman Coulter) or using the MoFlo cell sorter (Dakocytomation, Fort Collins, Colorado) and analysed using the Summit v4.11 software (Dakocytomation). Cells were gated on the basis of forward scatter and side scatter characteristics to exclude debris. PI was used as a viability stain to exclude all dead cells. Cells which were fluorescent for FDG above background were collected into 10%FCS/DMEM + 25 mM HEPES and placed on ice. At least 50 000 events were acquired for analysis. Sorted cells were immediately spun down at 300 × *g* for 4 min and resuspended in Trizol (Gibco BRL) for RNA extraction.

RT-PCR
------

Following RNA extraction, cDNA was synthesized using Superscript Reverse Transcriptase II (Invitrogen). Primers used were as follows: Tbx1-wt, Tbx1ex4-F 5′-TTTGTGCCCGTAGATGACAA-3′ and Tbx1ex6-R 5′-AATCGGGGCTGATATCTGTG-3′; Tbx1LacZ, IreslacZ-F 5′-TCGGTGCACATGCTTTACAT-3′ and IreslacZ-R 5′-GTTTTCCCAGTCACGACGTT-3′.

Microarray
----------

### Microarray hybridisation

Six *Df1*/*Tbx1*^*lacZ*^ samples and six *Tbx1*^+/*lacZ*^ samples were hybridised onto MOE430 v2 oligonucleotide array chips (Affymetrix) consisting of over 45 000 probe sets representing over 34 000 mouse genes. Purified, biotin-UTP labelled cRNA was fragmented and hybridised onto MOE430 v2 microarray chips according to Affymetrix protocols and this was carried out by the ICH Gene Microarray Centre (London UK). Arrays were scanned using the Affymetrix GeneChip Scanner and array images were captured using the Microarray Analysis Suite v5 software package (MAS, Affymetrix). The report files were examined to establish quality of the hybridisation.

### Genespring analysis

Genespring software version 4.2.1 (Silicon Genetics) was used for the comparison of *Df1*/*Tbx1*^*lacZ*^ and *Tbx1*^+/*lacZ*^ microarrays. Per chip normalisation used the 50th percentile of all measurements as a positive control for each sample. Measurements for each gene were divided by this synthetic positive control. The bottom tenth percentile was used as a test for correct background subtraction. Per gene normalisation was then carried out, for which all *Tbx1*^+/*lacZ*^ samples were normalised to 1 and all *Df1*/*Tbx1*^*lacZ*^ samples were normalised to the *Tbx1*^+/*lacZ*^ samples. The data from the mouse MOE430 v.2 microarray chips was then filtered to exclude genes with signals below the raw value of 22. Seventeen out of twenty *Df1* genes represented on the chip were expressed above threshold levels. Iterative analyses were then carried out on the normalised data to determine the appropriate filters to apply in order to successfully identify the hemizygously-expressed *Df1* genes. Gene lists were statistically analysed using the non-parametric *t*-test (Wilcoxon--Mann--Whitney/Kruskal--Wallis test) with a *p*-value cutoff of 0.05 and the Benjamini and Hochberg false discovery rate multiple testing correction was applied. Fourteen out of 17 *Df1* genes were downregulated to 0.83 in 5 out of 6 chips hybridised with the *Df1*/*Tbx1*^*lacZ*^ target under these conditions.

Quantitative real-time PCR
--------------------------

LacZ-expressing cells from a pool of at least 10 E9.5 *Df1*/*Tbx1*^+/−^ and *Tbx1*^+/−^ embryos were labelled using the CMFDG labelling kit (Molecular Probes) and collected by FACS. RNA was isolated using Trizol (Gibco BRL) and amplified by PCR-based amplification using the Microarray Target Amplification kit (Roche). Quantitative real-time PCR was carried out on the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). All reactions were performed in triplicate using SYBR green (Qiagen) under the following PCR conditions: 95 °C for 15 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min and expression values were obtained using the DART-PCR analysis excel software which takes into account the amplification efficiency of each gene to obtain relative quantities ([@bib40]) or by using the ΔΔCt method ([@bib63]). The qRT-PCR primers used can be found in the [supplementary data](#app1){ref-type="sec"} ([Supplementary Table 3](#app1){ref-type="sec"}).

Mouse embryo analysis
---------------------

*In situ* hybridization was performed according to previously published methods ([@bib58]). *Hes1*, *Fgf8*, *Fgf10* and *Etv4* probes were generated from cDNA plasmid clones. β-galactosidase activity was detected in embryos fixed in formaldehyde using X-gal (Promega) following standard procedures. Indian Ink (Pelikan) was injected into the outflow tract or aorta of embryos using a microinjection needle to visualise the pharyngeal arch arteries or great vessels of the heart. Multi-embryo magnetic resonance imaging (MRI) was carried out as described previously ([@bib51]) on embryos at E15.5. Following fixation, embryos were dehydrated and embedded in wax. Sections were cut at 8--12 µm and some were counterstained using Eosin. Paraffin or cryosections were used for immunofluorescence, 8--10 µm sections were stained using antibodies against Endomucin (Clone V.7C7 1/50, Santa Cruz), smooth muscle α-actin (Clone 1A4 1/700, Sigma), Hes1 (1/200, R. Kageyama), Tbx1 (1/100, Zymed, Invitrogen), β-galactosidase (1/300, Cappel), Isl1 (1/100, DSHB clones 402D6 and 394D5), phospho-Histone H3 (1/400, Upstate), Ki67 (1/25, Dako) and Caspase 3 (1/100, Cell Signaling). For analysis of cell death using a Caspase 3 antibody, neural crest cells were detected as mesenchymal cells negative for Isl1 or a β-galactosidase-encoding transgene expressed in pharyngeal mesoderm. Proliferation and cell death assays were carried out on *Hes1* mutant embryos in a CD1 mutant background. Data were obtained from four or more sections per embryo for three embryos per genotype. Equivalent cell numbers were scored in wild type and mutant embryos. Statistical analyses were carried out using Student\'s *t*-test. Dapi or Hoechst was used for counterstaining sections and the preparations were observed using an ApoTome microscope (Zeiss).
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![CMFDG labelling and analysis of *Tbx1LacZ* cell enrichment. Example of CMFDG labelling of an E9.5 *Df1*/*Tbx1*^*lacZ*^ embryo separated from the rest of the litter by phenotype. X-gal staining represents expression of the *Tbx1*^*lacZ*^ allele. This labelling procedure is also carried out on the *Tbx1*^+/*lacZ*^;*Df1*/+;wt pool of embryos. RT-PCR analysis indicates that the wild type *Tbx1* allele is present only in the FDG-positive cell population containing *Df1*/+ and *Tbx1*^+/*lacZ*^ cells. The *Tbx1LacZ* allele is only present in FDG-positive cell populations and represents *Df1*/*Tbx1*^*lacZ*^ and *Tbx1*^+/*lacZ*^ cells.](gr1){#fig1}

![Expression of *Hes1* in wild type and *Tbx1*^−/−^ embryos. (A--C) *Tbx1LacZ* expression at E9.5. (A) Whole embryo, (B) coronal section and (C) transverse section of *Tbx1*^+/*LacZ*^ embryo. (D) Transverse section illustrating *Hes1* expression at E9.5 by in situ hybridisation. (E--H) Whole mount in situ hybridisation (E--F) and corresponding transverse sections (G--H) showing *Hes1* expression is diminished in *Tbx1*^−/−−/−^ embryos. a indicates arch; ov, otic vesicle. (I) Overlapping expression of Hes1 and Tbx1 as detected by immunofluorescence staining of transverse cryosections of wild type E8.5 embryos. Pharyngeal mesenchyme is indicated by a black arrow, endoderm by a white arrowhead, mesoderm with a red arrowhead and ectoderm with a yellow arrowhead.](gr2){#fig2}

![Intracardiac ink injection of E10.5 *Hes1* mutants. (A) In wild type embryos, bilateral pairs of caudal PAAs R3--R6 and L3--L6 are present at E10.5. (B) A proportion of *Hes1*^+/−^ mutants have hypoplasia of the fourth arch artery (arrow) and persistent first and second arch arteries (C). *Hes1*^−/−^ mutants also exhibit fourth arch artery aplasia (arrow in D), persistent second arch arteries and aberrant branching of the arch arteries (arrow in E and inset) and sixth arch artery hypoplasia (arrow in F). L indicates left; R, right.](gr3){#fig3}

![*Hes1* mutants exhibit loss of vascular smooth muscle markers in the developing PAAs. (A, B) Immunofluorescence on coronal E10.5 embryo sections for the endothelial marker, Endomucin (Endo). Endo staining is present in wild type (A) and *Hes1*^−/−^ embryos with aplastic/non-patent 4th PAAs (arrow in B). (C, D) Immunofluorescence on coronal E11.5 embryo sections for α-SMA. Strong α-SMA expression surrounding the 3 rd, 4th and 6th PAA in wild types (C) is lost in the hypo/aplastic left 3 rd and 4th PAA (red and white arrows in D, respectively) of *Hes1*^−/−^ mutant embryos. The contralateral vessels, which have formed in this embryo, have normal α-SMA staining.](gr4){#fig4}

![22q11DS-like defects in E15.5 *Hes1*^−/−^ mutants. (A--D) Great vessel defects in E15.5 *Hes1*^−/−^ embryos. (A) Normal wild type (wt) great vessel morphology. (B--D) *Hes1*^−/−^ (--/--) mutants with RAA and right-sided ductus arteriosus (B), IAA-B and RAA (C), and I-RSA (D). (E) In wt embryos, the right subclavian artery branches off the right common carotid. (F) *Hes1*^−/−^ mutant in which the right subclavian branches off the pulmonary trunk. (G--L) OFT defects and VSD in *Hes1*^−/−^ mutants. (G, H) Transverse MRI scans. (I--L) Transverse histological sections. (G) In wild type embryos the interventricular septum separates the right and left ventricles. (H) *Hes1*^−/−^ mutants exhibit a VSD (dark staining represents blood). (I, J) Consecutive transverse sections of a wild type embryo in which the pulmonary trunk arises from the right ventricle (I) and the aorta joins the left ventricle (J). (K, L) Consecutive sections of a *Hes1*^−/−^ embryo with double outlet right ventricle in which both the aorta and pulmonary trunk arise from the right ventricle. (M, N) Transverse MRI sections of the palate at E15.5. (M) In wild type embryos the palatal shelves are fused. (N) *Hes1*^−/−^ mutants exhibit cleft palate where the palatal shelves do not meet in the midline. (O, P) Transverse MRI sections of the thymic lobes which are missing in *Hes1*^−/−^ mutants (P). ao indicates aorta; aoa, aortic arch; da, ductus arteriosus; ivs, interventricular septum; lcc, left common carotid; lsca, left subclavian artery; lv, left ventricle; ps, palatal shelf; pt, pulmonary trunk; rcc, right common carotid; rsca, right subclavian artery; rv, right ventricle; t, tongue; th, thymic lobe; vsd, ventricular septal defect. Asterisks indicate missing segments.](gr5){#fig5}

![22q11DS-like defects in E10.5 and E15.5 *Hes1* conditional mutants. (A--F) ROSAR26R reporter crosses. (A--C) *Hes1*^−/*fl*^;*Wnt1Cre* x ROSAR26R and (D--F) *Hes1*^−/*fl*^;*Ap2αCr*e x ROSAR26R crosses following X-gal staining. (A) E9.5 whole mount image, (B) sagittal section of (A) showing strong recombination in the neural crest of first and second pharyngeal arches (black arrows), and (C) transverse section of (A) showing recombination in the neural crest cells at the second heart field level (white arrow). (D) E9.5 whole mount image, (E) sagittal section of (D) showing strong recombination in the neural crest and ectoderm of first and second pharyngeal arches (black arrows) and (F) transverse section of (D) showing recombination in the ectoderm (black arrow) and neural crest cells (white arrow). (G--I) Great vessel defects in E15.5 *Hes1*^−/*fl*^;*Ap2αCre* embryos. (G) Normal *Hes1*^+/*fl*^ (wild type) great vessel morphology. (H--I) *Hes1*^−/*fl*^;*Ap2αCre* (Hes1 null in the ectoderm and neural crest) mutants with aberrant branching of the RCC (H) and I-RSA (I). (J) Intracardiac ink injection of E10.5 *Hes1*^−/*fl*^;*Ap2αCre* mutants displaying persistent second arch arteries (R2, L2) and unilateral third arch artery aplasia (arrow). (K--O) Thymic defects in E15.5 *Hes1*^−/*fl*^;*Ap2αCre* embryos. (K) Normal thymic lobe morphology in *Hes1*^+/*fl*^ (wild type) embryos. (L--M) Hypoplastic lobes (L) and a single, hypoplastic lobe (M) observed in *Hes1*^−/*fl*^;*Ap2αCre* mutants. (N--O) Transverse section of the thymic lobes in *Hes1*^−/*fl*^;*Ap2αCre* embryos showing normal development (N) and aplasia (O). aoa indicates the aortic arch; lcc, left common carotid; oft, outflow tract; rcc, right common carotid; rsca, right subclavian artery; rv, right ventricle; t, thymic lobe. Asterisks indicate missing or duplicated segments.](gr6){#fig6}

![Proliferation defect in *Hes1* mutants. (A--B) Immunohistochemistry with anti-phospho-Histone H3 (PH3) antibody in paraffin sections of E8.5 WT (A) and *Hes1*^−/−^ (B) embryos showing a decrease in PH3-positive cells within the surface ectoderm of *Hes1*^−/−^ mutants (arrowhead). (C--D) Immunohistochemistry with anti-Ki67 antibody in sections of E8.5 WT (C) and *Hes1*^−/−^ (D) embryos showing an increase in the number of Ki67-negative cells in *Hes1*^−/−^ embryos (arrowhead). (E) Graph comparing the percentage of PH3 positive cells and Ki67 negative cells in the pharyngeal ectoderm of WT embryos and *Hes1*^−/−^ mutants. A significant decrease in PH3 positive cells (*p* \< 0.05) and increase in Ki67 negative cells (*p* \< 0.05, Student\'s *t*-test) is observed in *Hes1*^−/−^ mutants.](gr7){#fig7}

###### 

*Df1* genes analysed by microarray.

  Gene                                     Relative expression in *Df1*/*Tbx1*^*lacZ*^ vs. *Tbx1*^+/*lacZ*^ cells
  ---------------------------------------- ------------------------------------------------------------------------
  Dgcr6                                    0.517 ± 0.068
  Zdhhc8                                   0.663 ± 0.140
  Ranbp1                                   0.598 ± 0.095
  Htf9c                                    0.549 ± 0.104
  D16h22s680e                              0.563 ± 0.267
  Arvcf                                    0.490 ± 0.165
  Comt                                     0.601 ± 0.118
  Txnrd2                                   0.531 ± 0.054
  Septin 5                                 0.568 ± 0.167
  Ufd1l                                    0.459 ± 0.091
  Slc25a1                                  0.639 ± 0.097
  Cdc45l                                   0.694 ± 0.206
  Prodh                                    0.632 ± 0.205
  Dgcr8                                    0.807 ± 0.153
  Cldn5[a](#tblfn1){ref-type="table-fn"}   0.752 ± 0.478
  Gnb1l[a](#tblfn1){ref-type="table-fn"}   0.706 ± 0.325
  Vpreb2 (L)                               0.749 ± 0.704
  Rtn4r (L)                                0.977 ± 0.631
  Tbx1 (L)                                 0.324 ± 0.344
  Es2el                                    1.459 ± 0.238

L indicates low signal strength.

These genes did not pass the filtering and statistical analysis applied.

###### 

Genes validated by qRT-PCR.

  Gene         Average relative expression in *Df1*/*Tbx1*^*lacZ*^ cells vs. *Tbx1*^+/*lacZ*^ cells (± SD)   Significance (\**p* \< 0.05, \*\**p* \< 0.01)   Reason for analysis
  ------------ --------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------
  Nkx2.6       0 ± 0                                                                                         \*\*                                            1 \#
  Cxcl4        0.133 ± 0.047                                                                                 \*\*                                            3
  Smad7        0.145 ± 0.094                                                                                 \*\*                                            2, 3
  Cdh1         0.201 ± 0.125                                                                                 \*\*                                            3
  Notch3       0.249 ± 0.103                                                                                 \*\*                                            2
  Hes1         0.261 ± 0.093                                                                                 \*\*                                            2, 3 \#
  Crb3         0.386 ± 0.058                                                                                 \*\*                                            3 \#
  Sema3c       0.360 ± 0.170                                                                                 \*\*                                            1, 3
  Pleckstrin   0.454 ± 0.019                                                                                 \*\*                                            3 \^
  Slit2        0.529 ± 0.125                                                                                 \*\*                                            2
  Lztfl1       0.562 ± 0.153                                                                                 \*\*                                            3
  Isl1         0.643 ± 0.153                                                                                 \*                                              1 \#
  Dsg2         0.656 ± 0.020                                                                                 \*\*                                            1, 3
  Bmpr1a       0.712 ± 0.116                                                                                 \*\*                                            1
  Tbx18        0.754 ± 0.140                                                                                 \*                                              1, 3 \#
  Tle4         0.783 ± 0.101                                                                                 \*                                              3
  Daam1        0.797 ± 0.152                                                                                 \*                                              2
  Gsk3b        0.831 ± 0.035                                                                                 \*\*                                            1, 2
  Dab2         0.721 ± 0.185                                                                                                                                 \# \^
  Pitx1        0.814 ± 0.134                                                                                                                                 2
  FoxP1        1.025 ± 0.349                                                                                                                                 1
  Socs3        1.051 ± 0.052                                                                                                                                 3
  Lrr16        1.001 ± 0.130                                                                                                                                 3
  Tmeff1       1.032 ± 0.270                                                                                                                                 3
  Ephb2        1.264 ± 0.312                                                                                                                                 1, 3
  Tbx20        0.981 ± 0.227                                                                                                                                 1
  Pafah1b2     0.956 ± 0.176                                                                                                                                 3
  Dkk1         1.908 ± 1.208                                                                                                                                 1 3 \#
  Cxcl12       1.048 ± 0.086                                                                                                                                 2 3
  Numb         1.493 ± 0.879                                                                                                                                 3

Values represent average changes in gene expression of *n* = 3 experiments (except for Dsg2 where *n* = 2).

Reasons for analysis:1.Known role in pharyngeal/heart development.2.Family members with a known role in pharyngeal/heart development in mice or other species.3.Stringently downregulated/multiple probes downregulated.

\#Downregulated in [@bib30].

\^Downregulated in [@bib20].

###### 

Frequency of pharyngeal arch artery defects in E10.5 *Hes1* mutants.

                                  WT         *Hes1*^+/−^                                 *Hes1*^−/−^
  ------------------------------- ---------- ------------------------------------------- ---------------------------------------------
  Total embryos                   77         80                                          40
  Total normal                    76         67                                          27
  Total abnormal (%)              1 (1%)     13[a](#tblfn2){ref-type="table-fn"} (16%)   13[a](#tblfn2){ref-type="table-fn"} (32.5%)
  Persistent 1st and/or 2nd PAA   --         2                                           6
  Hypo/aplastic 3rd PAA           --         --                                          1 (apl)
  Hypo/aplastic 4th PAA           1 (hypo)   8 (hypo)                                    3 (hypo), 3 (apl)
  Hypo/aplastic 6th PAA           --         --                                          1 (hypo)
  Aberrant branching              --         4                                           4

PAA, pharyngeal arch artery; hypo, hypoplastic; apl, aplastic.

Nb. Total WT embryos include additional WT non-littermates examined for the presence of PAA defects.

Significantly different from WT (Fisher\'s exact test *p* \< 0.01).

###### 

22q11DS-like defects observed at E14.5--E15.5.

  Strain        Genotype      *n*   Total CV defects                          Great vessel defect   OFT defect   Cleft Palate   Thymic hypo/aplasia
  ------------- ------------- ----- ----------------------------------------- --------------------- ------------ -------------- ---------------------
  MF1           *Hes1*^−/−^   15    2 (13%)                                   1                                  9 (60%)        13 (87%)
                *Hes1*^+/−^   15    1[a](#tblfn3){ref-type="table-fn"} (7%)   0                     0            0              0
                WT            2     0                                         0                     0            0              0
  MF1;C57Bl/6   *Hes1*^−/−^   23    5 (22%)                                   4                     2            9 (39%)        23 (100%)
                *Hes1*^+/−^   21    0                                         0                     0            1 (5%)         0
                WT            7     0                                         0                     0            0              0

CV --- cardiovascular, OFT --- outflow tract, WT --- wild type.

Dextroposition of the heart.

###### 

22q11DS-like defects observed at E15.5 in the *Hes1* conditional mutants.

  Strain        Genotype                   *n*   Total CV defects   Great vessel defect   OFT defect   Thymic hypo/aplasia
  ------------- -------------------------- ----- ------------------ --------------------- ------------ ---------------------
  MF1;C57Bl/6   *Hes1*^*fl*/−^;*Wnt1Cre*   26    0                  0                     0            10 (38.5%)
                *Hes1*^*fl*/+^;*Wnt1Cre*   31    0                  0                     0            2 (6.5%)
                *Hes1*^*fl*/−^             21    0                  0                     0            3 (14.3%)
                *Hes1*^*fl*/+^ (WT)        17    0                  0                     0            0
  MF1;C57Bl/6   *Hes1*^*fl*/−^;*Ap2αCre*   32    2 (6.25%)          2                     0            26 (81.3%)
                *Hes1*^*fl*/+^;*Ap2αCre*   20    0                  0                     0            0
                *Hes1*^*fl*/−^             23    0                  0                     0            2 (8.7%)
                *Hes1*^*fl*/+^ (WT)        27    0                  0                     0            2 (7.4%)

CV --- cardiovascular, OFT --- outflow tract, WT --- wild type.

[^1]: These investigators made an equal contribution to the work.
